Materials and Method: A total of 102 eyes of 102 patients diagnosed with nAMD were analyzed. The following information was retrospectively recorded from the patients? files: best-corrected visual acuity (BCVA) at baseline and at the 1-, 3-, 6-, and 12-month follow-ups; number of injections; central macular thickness (CMT) and presence of intraretinal and subretinal fluid.

Findings: In this study, the mean follow-up period was 12 months. Of the 102 patients, 49% were female. The mean age was 73.74±8.77. Forty-eight percent of the patients were treated with ranibizumab, and 52% were treated with aflibercept. There was no statistically significant difference in the mean number of injections between the ranibizumab group and the aflibercept group (p > 0.05), which was 3.65±1.45 and 3.77±1.51, respectively. In the 12-month follow-up period, there was no statistically significant difference in mean BCVA improvement between the two groups (p > 0.05). The number of patients with intraretinal fluid decreased by 38.8% in the ranibizumab group and by 24.5% in the aflibercept group (p > 0.05). The number of patients with subretinal fluid decreased by 34.7% in the ranibizumab group, while it decreased by 39.6% in the aflibercept group (p > 0.05).

Results: In nAMD, both ranibizumab and aflibercept injections reduce CMT, reduce the number of patients with intraretinal and subretinal fluid, and increase BCVA. Consequently, it was concluded that neither ranibizumab nor aflibercept is superior for intravitreal administration. Keywords : Aflibercept, Ranibizumab, Choroidal neovascularization, Age-related macular degeneration, Real life experience